KXAN15d
Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
This milestone builds on Clarity's earlier receipt of an FTD for 64 Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who ... review of novel drugs addressing serious ...
Taiwan News15d
Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for 64 Cu-SAR-bisPSMA for positron emission tomography (PET) imaging of ...